Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
Encorafenib en binimetinib bij niet-resectabel of gemetastaseerd BRAF-gemuteerd melanoom
apr 2019 | Dermato-oncologie